Barclays Maintains Equal-Weight on Editas Medicine, Lowers Price Target to $7
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Gena Wang maintains an Equal-Weight rating on Editas Medicine (NASDAQ:EDIT) but lowers the price target from $9 to $7.
August 08, 2024 | 6:44 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Barclays analyst Gena Wang maintains an Equal-Weight rating on Editas Medicine but lowers the price target from $9 to $7.
The lowered price target from $9 to $7 by Barclays suggests a less optimistic outlook for Editas Medicine, which could negatively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100